Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

TPEX:7871 Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Jul 8, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Debt / Equity Ratio	0.03	0.03	-1.09	-1.01
Net Debt / Equity Ratio	-1.01	-1.01	-1.02	-0.98
Net Debt / EBITDA Ratio	4.38	4.38	-6.05	-6.34
Net Debt / FCF Ratio	6.33	6.33	-5.18	-7.08
Asset Turnover	0.09	0.09	0.01	-
Quick Ratio	9.96	9.96	0.07	0.04
Current Ratio	10.03	10.03	0.07	0.04
Return on Assets (ROA)	-22.77%	-22.77%	-118.27%	-
Return on Capital Employed (ROCE)	-23.30%	-23.30%	17.40%	16.50%
Buyback Yield / Dilution	-256.61%	-256.61%	72.30%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 4, 2026

Data Sources Report a data error